Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kobayashi K, Sugiyama E, Shinozaki E, Wakatsuki T, Tajima M, Kidokoro H, Aoyama T, Nakano Y, Kawakami K, Hashimoto K, Suenaga M, Ichimura T, Ogura M, Chin K, Nakayama I, Ooki A, Takahari D, Suzuki W, Yokokawa T, Minowa Y, Hiraoka T, Suzuki K, Sato H, Hama T, Yamaguchi K.
Kobayashi K, et al.
Cancer Chemother Pharmacol. 2021 Jun;87(6):767-777. doi: 10.1007/s00280-021-04237-x. Epub 2021 Feb 26.
Cancer Chemother Pharmacol. 2021.
PMID: 33635392